Background: phenotypic approach in the treatment of COPD is lacking in general medical facilities, despite the importance of this data. Objectives: The study aimed to identify divergences in features, pharmacologic regimens of COPD by clinical phenotypes in the real-life context of care units in Can Tho City that manage outpatients with chronic respiratory diseases. Materials and methods: a prospective cohort study was carried out. We enrolled 158 patients who met the sampling criteria for this study. Data collected include (1) biometric characteristics, (2) medical history, (3) characteristics of COPD (including: symptoms, chest radiograph, peripheral blood eosinophil count, pulmonary ventilation parameters, bronchodilator test, and pharmacological regimen). COPD were classified into three phenotypic groups according to the criteria of the 2017 Spanish guideline (GesEPOC) and were also categorized into four groups (ABCD) according to the 2019 GOLD guideline. Results: the clinical AE phenotype was predominant at 41.8%, whereas the NON-AE and ACO was 38.6% and 19.6%. According to the GOLD, classifying as group A, B, C, D is 19%, 34.8%, 10.1%, and 36.1%, respectively. Between the different phenotypic groups, there were a variety of variances in the eosinophil count of the peripheral blood, but there were no changes in some kinds of chest radiograph images. Response-to-bronchodilator-test rate was higher in the ACO phenotype than in the NON-AE and the AE phenotypes. All ACO patients who received LABA/ICS. The proportion of using LABA/ICS accounted for most NON-AE and AE patients. Conclusions: among clinical phenotypes, the AE phenotype accounted for the highest percentage. There were differences in the clinical characteristics among phenotypes. ICS using is popular among COPD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.